Loading...

AdAlta Limited

1AD.AX•ASX
Healthcare
Biotechnology
A$0.005
A$0.001(25.00%)

AdAlta Limited (1AD.AX) Company Profile & Overview

Explore AdAlta Limited’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

AdAlta Limited (1AD.AX) Company Profile & Overview

AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. The company's lead i-body drug candidate includes AD-214, which is in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has collaborative partnerships with GE Healthcare to discover i-bodies that bind to granzyme B; and Carina Biotech Pty Ltd. to develop CAR-T cell products against various solid tumor antigens. AdAlta Limited was incorporated in 2006 and is headquartered in Bundoora, Australia.

SectorHealthcare
IndustryBiotechnology
CEOTimothy Charles Oldham BSc(Hons), LLB(Hons),

Contact Information

https://adalta.com.au
61394795159
Shop 14 330 Collins St, Melbourne, VIC, 3083

Company Facts

9 Employees
IPO DateAug 22, 2016
CountryAU
Actively Trading

Frequently Asked Questions

;